Tinnitus Market

Market Overview:

The 7 major tinnitus markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.02% during 2024-2034.

The tinnitus market has been comprehensively analyzed in IMARC's new report titled "Tinnitus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tinnitus refers to a medical condition characterized by a perception of ringing, buzzing, or other sounds in the ears or head that are not caused by an external sound source. The sounds can be continuous or intermittent and can vary in pitch and loudness. Individuals suffering from this ailment may experience phantom noises in the ears, such as roaring, clicking, hissing, humming, etc. In some cases, tinnitus can also manifest as a repetitive pulsating or whooshing sound, often in time with the heartbeat. These noises can be so loud that they impair a person’s ability to focus or hear external voices. The diagnosis of the disease involves a combination of taking a complete medical history, identifying the underlying indications, and performing various tests. An audiological exam is often performed by a healthcare professional to assess the tone and intensity of sounds, as well as issues linked to the function of the inner ear. Several diagnostic procedures, such as computed tomography scans and magnetic resonance imaging, are used to examine the interior structures of the ear and rule out other possible causes of tinnitus symptoms.

 The rising cases of ear infections, which can change the pressure in the ears or block the ear canals with a buildup of fluid, are primarily driving the tinnitus market. In addition to this, the expanding geriatric population, who are more prone to age-related hearing loss, that triggers random electrical impulses along the nerve from the ear to the brain, is also bolstering the market growth. Furthermore, the escalating adoption of potassium channel modulators and GABA transaminase inhibitors to suppress the symptoms of this ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cognitive behavioral therapy for the treatment of tinnitus, since it helps to gain control over negative thoughts and replace them with healthy emotions, thereby improving the quality of life among patients, is also creating a positive outlook for the market. Moreover, the introduction of various advanced minimally invasive techniques, such as electrical and magnetic stimulation of the ear, which boost deafferented auditory nerve fibers with little to no harm to hearing, is expected to drive the tinnitus market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the tinnitus market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for tinnitus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tinnitus market in any manner.

Key Highlights:

• Studies have revealed widely varying tinnitus prevalence, ranging from 4% to 37% globally and from 9% to 29% in Europe.
• Tinnitus affects roughly one out of every ten adults in the United States.
• The majority of research found that the prevalence of tinnitus in adults was between 8% and 30%.
• Men were affected far more frequently than women.
• Furthermore, mood disorder comorbidity among tinnitus patients has been shown to be as high as 60% to 80%, which might lead to an increase in tinnitus annoyance metrics.

Drugs:

AM-101 (Keyzilen), an esketamine gel for injection, has been developed to treat acute inner ear tinnitus. Esketamine is a strong, small-molecule NMDA receptor antagonist. Keyzilen is given in three intratympanic injections over 3-5 days. In two Phase 2 clinical trials, Keyzilen showed a favorable safety profile as well as a positive effect on subjective tinnitus loudness and other outcomes.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the tinnitus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the tinnitus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current tinnitus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the tinnitus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the tinnitus market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the tinnitus market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of tinnitus across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of tinnitus by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of tinnitus by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with tinnitus across the seven major markets?
• What is the size of the tinnitus patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of tinnitus?
• What will be the growth rate of patients across the seven major markets?
   

Tinnitus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for tinnitus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tinnitus market?
• What are the key regulatory events related to the tinnitus market?
• What is the structure of clinical trial landscape by status related to the tinnitus market?
• What is the structure of clinical trial landscape by phase related to the tinnitus market?
• What is the structure of clinical trial landscape by route of administration related to the tinnitus market?